NO20084792L - Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer - Google Patents

Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer

Info

Publication number
NO20084792L
NO20084792L NO20084792A NO20084792A NO20084792L NO 20084792 L NO20084792 L NO 20084792L NO 20084792 A NO20084792 A NO 20084792A NO 20084792 A NO20084792 A NO 20084792A NO 20084792 L NO20084792 L NO 20084792L
Authority
NO
Norway
Prior art keywords
carboxamides
cholecystokinin
substituted imidazole
receptor modulators
receptor
Prior art date
Application number
NO20084792A
Other languages
English (en)
Inventor
Richard Berger
Scott Edmondson
Alexa Hansen
Cheng Zhu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20084792L publication Critical patent/NO20084792L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)

Abstract

Visse nye substituerte imidazol-4-karboksamider er ligander for humankolecystokininreseptoren, og er særlig selektive ligander for humankolecystokinin-l-reseptoren (CCK-1R). De er derfor anvendbare til behandling, kontroll eller forebyggelse av sykdommer og forstyrrelser som gir respons på moduleringen av CCK-1R, slik som sykelig fedme og sukkersyke.
NO20084792A 2006-04-14 2008-11-13 Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer NO20084792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79196106P 2006-04-14 2006-04-14
PCT/US2007/008832 WO2007120655A2 (en) 2006-04-14 2007-04-10 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators

Publications (1)

Publication Number Publication Date
NO20084792L true NO20084792L (no) 2009-01-13

Family

ID=38606634

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084792A NO20084792L (no) 2006-04-14 2008-11-13 Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer

Country Status (16)

Country Link
US (2) US7795265B2 (no)
EP (1) EP2010519B1 (no)
JP (1) JP5155999B2 (no)
KR (1) KR20080110809A (no)
CN (1) CN101466698A (no)
AT (1) ATE515504T1 (no)
AU (1) AU2007238771B2 (no)
BR (1) BRPI0709972A2 (no)
CA (1) CA2649403C (no)
IL (1) IL194237A0 (no)
MX (1) MX2008013237A (no)
NO (1) NO20084792L (no)
NZ (1) NZ571412A (no)
RU (1) RU2008144962A (no)
WO (1) WO2007120655A2 (no)
ZA (1) ZA200807986B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
DE602007007594D1 (de) 2006-04-14 2010-08-19 Merck Sharp & Dohme Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
AU2007238804A1 (en) 2006-04-14 2007-10-25 Merck Sharp & Dohme Corp. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
CN101466698A (zh) * 2006-04-14 2009-06-24 默克公司 作为缩胆囊素-1受体调节剂的取代的咪唑4-甲酰胺类化合物
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2740735A4 (en) * 2011-08-05 2014-09-03 Teijin Ltd CONDENSED POLYCYCLIC AROMATIC COMPOUND, AROMATIC POLYMER, AND PROCESS FOR SYNTHESIZING AROMATIC COMPOUND
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
CN116332807A (zh) * 2023-03-24 2023-06-27 安徽秀朗新材料科技有限公司 一种3-（三氟甲基磺酰基）-2-萘甲酸甲酯的生产工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
WO2002055495A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7109216B2 (en) * 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
MXPA05011276A (es) 2003-04-21 2006-01-24 Daiichi Seiyaku Co Derivado heterociclico de cinco miembros.
US20050026983A1 (en) 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
KR20060117952A (ko) 2003-10-20 2006-11-17 솔베이 파마슈티칼스 비. 브이 카나비노이드 수용체 조절제로서 1ｈ-이미다졸 유도체
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
AU2005229459B9 (en) 2004-04-03 2009-01-22 Astrazeneca Ab Therapeutic agents
CN101027056A (zh) * 2004-09-16 2007-08-29 默克公司 用于治疗血脂异常和其它脂质病症的化合物
JP4860700B2 (ja) * 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンＨ３アンタゴニストとして有用な、１−［［１−［（２−アミノ−６−メチル−４−ピリジニル）メチル］−４−フルオロ−４−ピペリジニル］カルボニル］−４−［２−（２−ピリジニル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−３−イル］ピペリジン
AU2006331882A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
AU2007238804A1 (en) 2006-04-14 2007-10-25 Merck Sharp & Dohme Corp. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
CN101466698A (zh) * 2006-04-14 2009-06-24 默克公司 作为缩胆囊素-1受体调节剂的取代的咪唑4-甲酰胺类化合物
DE602007007594D1 (de) 2006-04-14 2010-08-19 Merck Sharp & Dohme Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren

Also Published As

Publication number Publication date
CN101466698A (zh) 2009-06-24
KR20080110809A (ko) 2008-12-19
BRPI0709972A2 (pt) 2011-08-02
US7795265B2 (en) 2010-09-14
US7977339B2 (en) 2011-07-12
EP2010519B1 (en) 2011-07-06
JP5155999B2 (ja) 2013-03-06
CA2649403C (en) 2011-06-21
ZA200807986B (en) 2009-10-28
US20100311649A1 (en) 2010-12-09
EP2010519A2 (en) 2009-01-07
WO2007120655A2 (en) 2007-10-25
IL194237A0 (en) 2009-09-22
MX2008013237A (es) 2009-03-06
WO2007120655A3 (en) 2008-09-25
ATE515504T1 (de) 2011-07-15
NZ571412A (en) 2010-07-30
US20090118300A1 (en) 2009-05-07
AU2007238771B2 (en) 2011-11-24
RU2008144962A (ru) 2010-05-20
CA2649403A1 (en) 2007-10-25
AU2007238771A1 (en) 2007-10-25
JP2009533444A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
NO20084792L (no) Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer
DE602007007594D1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
DE602007008868D1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
NO20091957L (no) Substituerte imidazoler som modulatorer for bombesinreseptor av undertype 3
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
DE602007009873D1 (de) Substituierte diazepin-sulfonamide als bombesin-rezeptor-subtyp-3-modulatoren
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
ATE473741T1 (de) Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
EP2114408A4 (en) SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS
WO2008051404A3 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
MX2007002583A (es) Metodos y composiciones para realzar la degradacion de factores de transcripcion del receptor nuclear y sus usos.
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application